StockNews.com Begins Coverage on Curis (NASDAQ:CRIS)

Analysts at StockNews.com began coverage on shares of Curis (NASDAQ:CRIS) in a report issued on Saturday. The firm set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Curis in a report on Tuesday, December 10th.

Curis Stock Down 3.7 %

Shares of Curis stock opened at $2.32 on Friday. The company has a market capitalization of $19.64 million, a price-to-earnings ratio of -0.30 and a beta of 3.49. The stock’s 50-day simple moving average is $3.04 and its 200-day simple moving average is $3.90. Curis has a 52 week low of $2.30 and a 52 week high of $17.49.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. CM Management LLC lifted its position in shares of Curis by 83.3% in the fourth quarter. CM Management LLC now owns 220,000 shares of the biotechnology company’s stock worth $673,000 after buying an additional 100,000 shares in the last quarter. Focused Wealth Management Inc increased its stake in Curis by 9.5% in the 4th quarter. Focused Wealth Management Inc now owns 59,204 shares of the biotechnology company’s stock worth $181,000 after acquiring an additional 5,138 shares during the last quarter. Millennium Management LLC raised its holdings in shares of Curis by 92.6% during the 4th quarter. Millennium Management LLC now owns 25,557 shares of the biotechnology company’s stock worth $78,000 after acquiring an additional 12,287 shares in the last quarter. Squarepoint Ops LLC bought a new position in shares of Curis during the 4th quarter valued at approximately $35,000. Finally, Alyeska Investment Group L.P. purchased a new position in shares of Curis in the fourth quarter valued at $607,000. Institutional investors own 29.97% of the company’s stock.

About Curis

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.